Protocol Ledger

NCT03395132 · Phase III · TERMINATED

Efficacy and Safety of Fucicort® Lipid Cream Compared to Combination Treatment With Fucidin® Cream Followed by Betamethasone (Lianbang Beisong®) Cream and Fucicort® Lipid Cream Vehicle in Clinically Infected Atopic Derma

Interventional Phase III clinical trial protocol NCT03395132 sponsored by LEO Pharma in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-07-31 Enrollment: 68 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03395132
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)68 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03395132
Protocol FieldVerified Registry Value
NCT IdentifierNCT03395132
Consolidated Lead SponsorLEO Pharma
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment68 participants (ACTUAL)
Registered Start Date2018-07-31
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI